A clinical trial at Xinqiao Hospital of the Third Military Medical University investigated the clinical benefits of the combination of ginsenoside and an EGFR-TKI in the treatment of advanced non-small cell carcinoma in patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.